Designing CD4 immunoadhesins for AIDS therapy
Abstract
A newly-constructed antibody-like molecule containing the gp!20-binding domain of the receptor for human immunodeficiency virus blocks HIV-1 infection of T cells and monocytes. Its long plasma half-life, other antibody-like properties, and potential to block all HIV isolates, make it a good candidate for therapeutic use.
- Publication:
-
Nature
- Pub Date:
- February 1989
- DOI:
- 10.1038/337525a0
- Bibcode:
- 1989Natur.337..525C